AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 24467565 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin degludec (IDeg) 0.4 U/kg
Number of subjects: 37
Study 24467565 — intervention group
Group type: COMPARATOR
Intervention: Insulin glargine (IGlar)
Number of subjects: 37
Study 22479361 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose vitamin A (200,000 IU) in addition to daily low-dose vitamin A (5000 IU) for 15 days.
Number of subjects: 260
Study 22479361 — intervention group
Group type: COMPARATOR
Intervention: Placebo in addition to daily low-dose vitamin A (5000 IU) for 15 days.
Number of subjects: 260
Study 19017676 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher dose exercise programme (60 min/day) conducted whilst standing
Number of subjects: 160
Study 19017676 — intervention group
Group type: COMPARATOR
Intervention: Lower dose exercise programme (30 min/day) primarily conducted whilst seated/supine
Number of subjects: 160
Study 17515696 — intervention group
Group type: EXPERIMENTAL
Intervention: Cinacalcet HCl (90 mg) following a high-fat, high-caloric meal
Number of subjects: 30
Study 17515696 — intervention group
Group type: EXPERIMENTAL
Intervention: Cinacalcet HCl (90 mg) following a low-fat, low-caloric meal
Number of subjects: 30
Study 17515696 — intervention group
Group type: COMPARATOR
Intervention: Cinacalcet HCl (90 mg) under fasting conditions
Number of subjects: 30
Study 17515696 — intervention group
Group type: EXPERIMENTAL
Intervention: Cinacalcet HCl (90 mg) following high-fat meal
Number of subjects: 30
Study 17515696 — intervention group
Group type: EXPERIMENTAL
Intervention: Cinacalcet HCl (90 mg) following low-fat meal
Number of subjects: 30
Study 17515696 — intervention group
Group type: EXPERIMENTAL
Intervention: Cinacalcet HCl (90 mg) across all treatment conditions
Number of subjects: 30
Study 15126996 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise training for 8 weeks
Number of subjects: 14
Study 15126996 — intervention group
Group type: COMPARATOR
Intervention: Matched control subjects
Number of subjects: 14
Study 10869738 — intervention group
Group type: EXPERIMENTAL
Intervention: Boost of 16 Gy to the primary tumor bed
Number of subjects: 5569
Study 10869738 — intervention group
Group type: COMPARATOR
Intervention: No further treatment (no boost)
Number of subjects: 5569
Study 10869738 — intervention group
Group type: EXPERIMENTAL
Intervention: Panel evaluation
Number of subjects: 5569
Study 10869738 — intervention group
Group type: EXPERIMENTAL
Intervention: Digitizer measurements
Number of subjects: 5569
Study 9184703 — intervention group
Group type: EXPERIMENTAL
Intervention: Glimepiride 3 mg twice daily
Number of subjects: 161
Study 9184703 — intervention group
Group type: EXPERIMENTAL
Intervention: Glimepiride 6 mg once daily
Number of subjects: 161
Study 9184703 — intervention group
Group type: COMPARATOR
Intervention: Glimepiride (both regimens)
Number of subjects: 161
Study 1589410 — intervention group
Group type: COMPARATOR
Intervention: Nasal spray formulation without STDHF
Number of subjects: 0
Study 1589410 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal formulations containing 3% (w/v) of STDHF
Number of subjects: 0
Study 1589410 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal formulations containing 1.65% (w/v) of STDHF
Number of subjects: 0
Study 1589410 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal formulations containing 1.2% (w/v) of STDHF
Number of subjects: 0
Study 1589410 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal formulations containing 0.8% (w/v) of STDHF
Number of subjects: 0
Study 1589410 — intervention group
Group type: EXPERIMENTAL
Intervention: All STDHF-containing sprays
Number of subjects: 0
Study 3890600 — intervention group
Group type: EXPERIMENTAL
Intervention: terbutaline delivered by a pressurized aerosol with a tube spacer (TS)
Number of subjects: 24
Study 3890600 — intervention group
Group type: EXPERIMENTAL
Intervention: salbutamol from a dry powder inhaler (Rotahaler = RO)
Number of subjects: 24
Study 3890600 — intervention group
Group type: EXPERIMENTAL
Intervention: tube spacer (TS)
Number of subjects: 24
Study 3890600 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 24
Study 2957205 — intervention group
Group type: EXPERIMENTAL
Intervention: Piroxicam
Number of subjects: 26
Study 2957205 — intervention group
Group type: COMPARATOR
Intervention: Naproxen
Number of subjects: 26
Study 30336205 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive Glycemic Control (IGC; HbA1c target < 6.0%)
Number of subjects: 124
Study 30336205 — intervention group
Group type: COMPARATOR
Intervention: Standard Glycemic Control (SGC; HbA1c target 7.0% to 7.9%)
Number of subjects: 124
Study 30336205 — intervention group
Group type: EXPERIMENTAL
Intervention: Mean HbA1c
Number of subjects: 124
Study 30336205 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-randomization mean HbA1c
Number of subjects: 124
Study 27893539 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiofrequency (RF) treatment
Number of subjects: 30
Study 27893539 — intervention group
Group type: COMPARATOR
Intervention: Pulsed Dye Laser (PDL) treatment
Number of subjects: 30
Study 26131788 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile training video for explosives scenario
Number of subjects: 90
Study 26131788 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile training video for chemical nerve agent scenario
Number of subjects: 90
Study 26131788 — intervention group
Group type: COMPARATOR
Intervention: Radiologic scenario (no intervention)
Number of subjects: 90
Study 26131788 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive posttest scores
Number of subjects: 90
Study 23130943 — intervention group
Group type: EXPERIMENTAL
Intervention: Auricular acupressure applied to six true acupoints (shenmen, Kidney, Liver, Internal Genitals, Central Rim, and Endocrine) for 1 minute, 4 times a day for 2 days.
Number of subjects: 113
Study 23130943 — intervention group
Group type: COMPARATOR
Intervention: Sham acupressure applied to six sham acupoints for 1 minute, 4 times a day for 2 days.
Number of subjects: 113
Study 21134121 — intervention group
Group type: EXPERIMENTAL
Intervention: 5u/mL BTX‐A
Number of subjects: 60
Study 21134121 — intervention group
Group type: COMPARATOR
Intervention: 0.5% lidocaine
Number of subjects: 60
Study 21134121 — intervention group
Group type: COMPARATOR
Intervention: 0.9% saline (placebo)
Number of subjects: 60
Study 18227701 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported freckling when sunbathing
Number of subjects: 2000
Study 18227701 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported sunbathing vacations to southern latitudes
Number of subjects: 2000
Study 18227701 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported solarium use in the last 5 years
Number of subjects: 2000
Study 18227701 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported sunscreen use (yes/no) on specific occasions
Number of subjects: 2000
Study 18227701 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported SPF on sunbathing vacations to southern latitudes (today)
Number of subjects: 2000
Study 18227701 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported SPF on sunbathing vacations to southern latitudes (10 years ago)
Number of subjects: 2000
Study 18227701 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported sunscreen brand use (yes/no)
Number of subjects: 2000
Study 18227701 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported SPF for sunscreen brands
Number of subjects: 2000
Study 18227701 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported frequency of sunburn
Number of subjects: 2000
Study 18227701 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported frequency of sunbathing vacations in Norway or outside southern latitudes
Number of subjects: 2000
Study 16513202 — intervention group
Group type: EXPERIMENTAL
Intervention: Morning insulin glargine
Number of subjects: 62
Study 16513202 — intervention group
Group type: COMPARATOR
Intervention: Bedtime NPH
Number of subjects: 62
Study 12948920 — intervention group
Group type: COMPARATOR
Intervention: 0.005% calcipotriol alone once daily (monotherapy)
Number of subjects: 61
Study 12948920 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.004% calcipotriol/0.01% clobetasol propionate as a premixed ointment once daily (combination therapy)
Number of subjects: 61
Study 10784636 — intervention group
Group type: EXPERIMENTAL
Intervention: Finasteride (intervention group)
Number of subjects: 18882
Study 9182470 — intervention group
Group type: EXPERIMENTAL
Intervention: Zidovudine
Number of subjects: 270
Study 9182470 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 270
Study 1586684 — intervention group
Group type: EXPERIMENTAL
Intervention: O-System (OS)
Number of subjects: 60
Study 1586684 — intervention group
Group type: COMPARATOR
Intervention: System II (CS)
Number of subjects: 60
Study 3897499 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent lumbar punctures
Number of subjects: 47
Study 3897499 — intervention group
Group type: COMPARATOR
Intervention: Supportive care only (Control)
Number of subjects: 47
Study 30649257 — intervention group
Group type: EXPERIMENTAL
Intervention: Piezocision (surgical protocol with sutures)
Number of subjects: 24
Study 30649257 — intervention group
Group type: COMPARATOR
Intervention: Control group (without any further treatment)
Number of subjects: 24
Study 29562486 — intervention group
Group type: EXPERIMENTAL
Intervention: New cold modality targeting upper normal therapeutic temperature range
Number of subjects: 53
Study 29562486 — intervention group
Group type: COMPARATOR
Intervention: Ice pack therapy
Number of subjects: 53
Study 27573936 — intervention group
Group type: COMPARATOR
Intervention: THCV (5 mg twice daily)
Number of subjects: 62
Study 27573936 — intervention group
Group type: COMPARATOR
Intervention: CBD (100 mg twice daily)
Number of subjects: 62
Study 27573936 — intervention group
Group type: COMPARATOR
Intervention: Combination treatments (1:1 ratio of CBD and THCV (5 mg/5 mg, twice daily) and 20:1 ratio of CBD and THCV (100 mg/5 mg, twice daily))
Number of subjects: 62
Study 27573936 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 62
Study 26302251 — intervention group
Group type: EXPERIMENTAL
Intervention: Bounce Back intervention (10-session cognitive-behavioral group intervention)
Number of subjects: 74
Study 26302251 — intervention group
Group type: COMPARATOR
Intervention: Delayed intervention (3-month waitlist)
Number of subjects: 74
Study 23809278 — intervention group
Group type: EXPERIMENTAL
Intervention: Ulipristal acetate (UPA) 30 mg
Number of subjects: 163
Study 23809278 — intervention group
Group type: EXPERIMENTAL
Intervention: Levonorgestrel (LNG) 1.5 mg
Number of subjects: 163
Study 23809278 — intervention group
Group type: EXPERIMENTAL
Intervention: Levonorgestrel (LNG) 1.5 mg + meloxicam 15 mg
Number of subjects: 163
Study 23809278 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 163
Study 20884177 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine CR 40 mg
Number of subjects: 37
Study 20884177 — intervention group
Group type: COMPARATOR
Intervention: Diltiazem R 100 mg
Number of subjects: 37
Study 18203086 — intervention group
Group type: EXPERIMENTAL
Intervention: Latanoprost-timolol maleate fixed combination (LTFC) administered at 8 PM (Group 1)
Number of subjects: 30
Study 18203086 — intervention group
Group type: EXPERIMENTAL
Intervention: Latanoprost-timolol maleate fixed combination (LTFC) administered at 8 AM (Group 2)
Number of subjects: 30
Study 18203086 — intervention group
Group type: COMPARATOR
Intervention: Latanoprost therapy alone (Control)
Number of subjects: 30
Study 16369463 — intervention group
Group type: EXPERIMENTAL
Intervention: 8-weeks of RR training using audiotapes (n=34)
Number of subjects: 46
Study 16369463 — intervention group
Group type: COMPARATOR
Intervention: Health-education control condition (n=12)
Number of subjects: 46
Study 12698048 — intervention group
Group type: EXPERIMENTAL
Intervention: Lowering of intraocular pressure (IOP) by 30% or more
Number of subjects: 0
Study 12698048 — intervention group
Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 0
Study 12698048 — intervention group
Group type: EXPERIMENTAL
Intervention: Lowering of IOP
Number of subjects: 0
Study 10698329 — intervention group
Group type: EXPERIMENTAL
Intervention: Botulinum toxin A (BTX/A)
Number of subjects: 16
Study 10698329 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 9524791 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular meloxicam (15 mg) on Day 1 followed by oral meloxicam (15 mg/day) for 7 days
Number of subjects: 169
Study 9524791 — intervention group
Group type: COMPARATOR
Intervention: Intramuscular piroxicam (20 mg) on Day 1 followed by oral piroxicam (20 mg/day) for 7 days
Number of subjects: 169
Study 1283411 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified technique for the Gillies temporal approach without hair removal
Number of subjects: 2
Study 1283411 — intervention group
Group type: COMPARATOR
Intervention: Modified technique for the Gillies temporal approach with hair removal
Number of subjects: 2
Study 3513719 — intervention group
Group type: EXPERIMENTAL
Intervention: Three injection regimen (delaying evening intermediate acting insulin to bedtime)
Number of subjects: 18
Study 3513719 — intervention group
Group type: COMPARATOR
Intervention: Conventional insulin regimen (evening intermediate acting insulin before the evening meal)
Number of subjects: 18
Study 30585526 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary radical prostatectomy (RP) with extended pelvic lymph-node dissection and adjuvant or salvage radiation therapy (RT) and/or androgen deprivation therapy (ADT) if deemed necessary.
Number of subjects: 400
Study 30585526 — intervention group
Group type: COMPARATOR
Intervention: Primary radiation treatment (RT) plus androgen deprivation treatment (ADT).
Number of subjects: 400
Study 27004726 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental regimen (3 or 4 months duration)
Number of subjects: 80
Study 27004726 — intervention group
Group type: EXPERIMENTAL
Intervention: STEP trial with 80 patients per arm
Number of subjects: 80
Study 25769201 — intervention group
Group type: EXPERIMENTAL
Intervention: TightRope fixation
Number of subjects: 43
Study 25769201 — intervention group
Group type: COMPARATOR
Intervention: Syndesmotic screw fixation
Number of subjects: 43
Study 25769201 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 43
Study 24392223 — intervention group
Group type: EXPERIMENTAL
Intervention: intensive counseling plus smartphone intervention
Number of subjects: 68
Study 24392223 — intervention group
Group type: EXPERIMENTAL
Intervention: less intensive counseling plus smartphone intervention
Number of subjects: 68
Study 24392223 — intervention group
Group type: COMPARATOR
Intervention: intensive counseling intervention
Number of subjects: 68
Study 24392223 — intervention group
Group type: COMPARATOR
Intervention: smartphone intervention only
Number of subjects: 68
Study 20406214 — intervention group
Group type: EXPERIMENTAL
Intervention: Grapefruit juice (200 ml t.i.d. for 5 days)
Number of subjects: 12
Study 20406214 — intervention group
Group type: COMPARATOR
Intervention: Water (control)
Number of subjects: 12
Study 17965148 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin 600 mg single-dose
Number of subjects: 204
Study 17965148 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 204
Study 15974146 — intervention group
Group type: EXPERIMENTAL
Intervention: CD-ROM preventive intervention (n = 61)
Number of subjects: 123
Study 15974146 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 62)
Number of subjects: 123
Study 12754171 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperthermia trial
Number of subjects: 8
Study 12754171 — intervention group
Group type: COMPARATOR
Intervention: Control trial
Number of subjects: 8
Study 10368494 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal estradiol (2 mg twice daily)
Number of subjects: 10
Study 10368494 — intervention group
Group type: COMPARATOR
Intervention: Oral estradiol (2 mg twice daily)
Number of subjects: 10
Study 8694680 — intervention group
Group type: EXPERIMENTAL
Intervention: Acamprosate
Number of subjects: 272
Study 8694680 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 272
Study 2015735 — intervention group
Group type: EXPERIMENTAL
Intervention: Triazolam, 0.5 mg
Number of subjects: 18
Study 2015735 — intervention group
Group type: EXPERIMENTAL
Intervention: Temazepam, 30 mg
Number of subjects: 18
Study 2015735 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 7089798 — intervention group
Group type: EXPERIMENTAL
Intervention: Coffee (active drug)
Number of subjects: 0
Study 7089798 — intervention group
Group type: COMPARATOR
Intervention: Decaffeinated coffee (placebo)
Number of subjects: 0
Study 29781308 — intervention group
Group type: EXPERIMENTAL
Intervention: Intralesional triamcinolone injection
Number of subjects: 48
Study 29781308 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.05% clobetasol ointment
Number of subjects: 48
Study 29781308 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 48
Study 28317683 — intervention group
Group type: EXPERIMENTAL
Intervention: Femtosecond laser-created CCI
Number of subjects: 20
Study 28317683 — intervention group
Group type: COMPARATOR
Intervention: Manual CCI
Number of subjects: 20
Study 26134462 — intervention group
Group type: EXPERIMENTAL
Intervention: Standing position breathing exercises with positive expiratory pressure
Number of subjects: 189
Study 26134462 — intervention group
Group type: COMPARATOR
Intervention: Sitting position breathing exercises with positive expiratory pressure
Number of subjects: 189
Study 23817976 — intervention group
Group type: EXPERIMENTAL
Intervention: Motor rTMS sessions for 2 weeks
Number of subjects: 18
Study 23817976 — intervention group
Group type: COMPARATOR
Intervention: Sham rTMS sessions for 2 weeks
Number of subjects: 18
Study 21763211 — intervention group
Group type: EXPERIMENTAL
Intervention: Duloxetine treatment
Number of subjects: 797
Study 18437470 — intervention group
Group type: EXPERIMENTAL
Intervention: Encouragement to resume daily physical activity with standardized advice and individualized activity goals
Number of subjects: 64
Study 18437470 — intervention group
Group type: COMPARATOR
Intervention: Standard care (control group)
Number of subjects: 64
Study 18437470 — intervention group
Group type: EXPERIMENTAL
Intervention: Encouragement to resume daily physical activity
Number of subjects: 64
Study 16920590 — intervention group
Group type: EXPERIMENTAL
Intervention: 24-hour head bandage
Number of subjects: 80
Study 16920590 — intervention group
Group type: COMPARATOR
Intervention: 10-day head bandage
Number of subjects: 80
Study 15241710 — intervention group
Group type: EXPERIMENTAL
Intervention: Heading group
Number of subjects: 31
Study 15241710 — intervention group
Group type: COMPARATOR
Intervention: Kicking group
Number of subjects: 31
Study 11408507 — intervention group
Group type: EXPERIMENTAL
Intervention: HEC (epirubicin 100 mg/m², cyclophosphamide 830 mg/m²; day 1 every 3 weeks)
Number of subjects: 255
Study 11408507 — intervention group
Group type: EXPERIMENTAL
Intervention: EC (epirubicin 60 mg/m², cyclophosphamide 500 mg/m²; day 1 every 3 weeks)
Number of subjects: 255
Study 11408507 — intervention group
Group type: COMPARATOR
Intervention: CMF (oral cyclophosphamide for six cycles)
Number of subjects: 255
Study 9208358 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril (20 mg once daily)
Number of subjects: 27
Study 9208358 — intervention group
Group type: COMPARATOR
Intervention: Captopril (75 mg thrice daily)
Number of subjects: 27
Study 7778531 — intervention group
Group type: EXPERIMENTAL
Intervention: Delapril
Number of subjects: 0
Study 7778531 — intervention group
Group type: COMPARATOR
Intervention: Captopril
Number of subjects: 0
Study 2399180 — intervention group
Group type: EXPERIMENTAL
Intervention: Chloral hydrate (50 mg/kg)
Number of subjects: 30
Study 2399180 — intervention group
Group type: COMPARATOR
Intervention: Diazepam (0.3 mg/kg)
Number of subjects: 30
Study 2399180 — intervention group
Group type: COMPARATOR
Intervention: Diazepam (0.6 mg/kg)
Number of subjects: 30
Study 386715 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 g L-tryptophan daily
Number of subjects: 58
Study 386715 — intervention group
Group type: COMPARATOR
Intervention: 150 mg imipramine daily
Number of subjects: 58
Study 31113177 — intervention group
Group type: EXPERIMENTAL
Intervention: Strength Training Group (STG)
Number of subjects: 28
Study 31113177 — intervention group
Group type: COMPARATOR
Intervention: Control Group (CG)
Number of subjects: 28
Study 28100544 — intervention group
Group type: EXPERIMENTAL
Intervention: Oscillatory whole-body vibration (WBV) - 16 sessions of 1-hour duration within 4 weeks
Number of subjects: 22
Study 28100544 — intervention group
Group type: EXPERIMENTAL
Intervention: Oscillatory whole-body vibration (WBV)
Number of subjects: 22
Study 28100544 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined analysis of all patients (n=22)
Number of subjects: 22
Study 25049195 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment focusing on weight and behavioral symptoms
Number of subjects: 63
Study 25049195 — intervention group
Group type: COMPARATOR
Intervention: Treatment focusing solely on improving QoL
Number of subjects: 63
Study 24938369 — intervention group
Group type: EXPERIMENTAL
Intervention: Menthol smoking
Number of subjects: 1439
Study 24938369 — intervention group
Group type: COMPARATOR
Intervention: Non-menthol smoking
Number of subjects: 1439
Study 24938369 — intervention group
Group type: EXPERIMENTAL
Intervention: Menthol smoking (AA women)
Number of subjects: 1439
Study 24938369 — intervention group
Group type: EXPERIMENTAL
Intervention: Menthol smoking (white women)
Number of subjects: 1439
Study 24938369 — intervention group
Group type: EXPERIMENTAL
Intervention: Menthol smoking (AA males)
Number of subjects: 1439
Study 24938369 — intervention group
Group type: EXPERIMENTAL
Intervention: Menthol smoking (white males)
Number of subjects: 1439
Study 23174473 — intervention group
Group type: EXPERIMENTAL
Intervention: Running group (30 minutes of running every morning at moderate intensity for 3 weeks)
Number of subjects: 51
Study 23174473 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 51
Study 21056284 — intervention group
Group type: EXPERIMENTAL
Intervention: Orange juice (OJ) concentrate, 750 mL/day for 60 days
Number of subjects: 45
Study 21056284 — intervention group
Group type: COMPARATOR
Intervention: Control group (no OJ consumption for 60 days)
Number of subjects: 45
Study 17599421 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive-care guidelines
Number of subjects: 2977
Study 17599421 — intervention group
Group type: COMPARATOR
Intervention: Standard-care guidelines
Number of subjects: 2977